RU2001134298A - The use of cortisol antagonists in the treatment of heart failure - Google Patents

The use of cortisol antagonists in the treatment of heart failure

Info

Publication number
RU2001134298A
RU2001134298A RU2001134298/14A RU2001134298A RU2001134298A RU 2001134298 A RU2001134298 A RU 2001134298A RU 2001134298/14 A RU2001134298/14 A RU 2001134298/14A RU 2001134298 A RU2001134298 A RU 2001134298A RU 2001134298 A RU2001134298 A RU 2001134298A
Authority
RU
Russia
Prior art keywords
heart
cortisol
heart failure
use according
treatment
Prior art date
Application number
RU2001134298/14A
Other languages
Russian (ru)
Other versions
RU2245712C2 (en
Inventor
Пер МАРИН
Стен СЁРЕНСЕН
Original Assignee
Кортендо АБ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9915625.9A external-priority patent/GB9915625D0/en
Application filed by Кортендо АБ filed Critical Кортендо АБ
Publication of RU2001134298A publication Critical patent/RU2001134298A/en
Application granted granted Critical
Publication of RU2245712C2 publication Critical patent/RU2245712C2/en

Links

Claims (12)

1. Применение антагониста кортизола в изготовлении лекарства для лечения сердечной недостаточности.1. The use of a cortisol antagonist in the manufacture of a medicament for the treatment of heart failure. 2. Применение по п.1, где сердечная недостаточность классифицируется как застойная, диастолическая, гипосистолическая или правосторонняя сердечная недостаточность.2. The use according to claim 1, where heart failure is classified as congestive, diastolic, hyposystolic or right-sided heart failure. 3. Применение по п.1 или 2, где антагонист кортизола представляет собой ингибитор синтеза кортизола.3. The use according to claim 1 or 2, where the cortisol antagonist is an inhibitor of cortisol synthesis. 4. Применение по п.3, где ингибитор синтеза кортизола представляет собой кетоконазол или его производное.4. The use of claim 3, wherein the cortisol synthesis inhibitor is ketoconazole or a derivative thereof. 5. Применение по п.4, где ингибитор синтеза кортизола представляет собой цис-2S, 2R и/или цис-2R,4S изомер кетоконазола.5. The use according to claim 4, where the cortisol synthesis inhibitor is cis-2S, 2R and / or cis-2R, 4S isomer of ketoconazole. 6. Применение по любому из пп.1-5, где лекарство предназначено для лечения увеличения сердца или фиброза в сердечной мышце.6. The use according to any one of claims 1 to 5, where the drug is intended to treat enlargement of the heart or fibrosis in the heart muscle. 7. Применение антагониста кортизола в изготовлении лекарства для лечения одного или более чем одного симптома, связанного с сердечной недостаточностью, выбранного из группы, включающей в себя отек нижних конечностей, отек легких, диспноэ, увеличение печени, повышенную частоту сердечных сокращений, уменьшенный ударный объем сердца, одышку и непереносимость физических нагрузок.7. The use of a cortisol antagonist in the manufacture of a medicament for the treatment of one or more than one symptom associated with heart failure, selected from the group consisting of edema of the lower extremities, pulmonary edema, dyspnea, enlarged liver, increased heart rate, decreased stroke volume of the heart , shortness of breath and exercise intolerance. 8. Применение по п.7, где лекарство предназначено для лечения отека легких.8. The use according to claim 7, where the medicine is intended to treat pulmonary edema. 9. Применение по любому из пп.1-8, где суточная доза антагониста кортизола, которой лечат пациента, составляет 100-1200 мг.9. The use according to any one of claims 1 to 8, where the daily dose of the cortisol antagonist, which is treated by the patient, is 100-1200 mg. 10. Способ лечения сердечной недостаточности у млекопитающего, при котором указанному млекопитающему вводят фармацевтически эффективное количество антагониста кортизола.10. A method of treating heart failure in a mammal, wherein a pharmaceutically effective amount of a cortisol antagonist is administered to said mammal. 11. Способ лечения одного или более чем одного симптома, связанного с сердечной недостаточностью, выбранного из группы, включающей в себя отек нижних конечностей, отек легких, диспноэ, увеличение печени, повышенную частоту сердечных сокращений, уменьшенный ударный объем сердца, одышку и непереносимость физических нагрузок, у млекопитающего, при котором указанному млекопитающему вводят фармацевтически эффективное количество антагониста кортизола.11. A method of treating one or more than one symptom associated with heart failure, selected from the group including lower extremity edema, pulmonary edema, dyspnea, enlarged liver, increased heart rate, decreased heart stroke volume, shortness of breath and exercise intolerance , in a mammal in which a pharmaceutically effective amount of a cortisol antagonist is administered to said mammal. 12. Продукт, содержащий (а) антагонист кортизола и (б) второе лекарственное средство, в качестве комбинированного препарата для применения одновременно, раздельно или последовательно при лечении сердечной недостаточности или для улучшения функции сердца и уменьшения непереносимости физических нагрузок.12. A product containing (a) a cortisol antagonist and (b) a second drug, as a combined drug for use simultaneously, separately or sequentially in the treatment of heart failure or to improve heart function and reduce exercise intolerance.
RU2001134298/14A 1999-07-02 2000-07-03 Method for applying cortisol antagonists at treating heart failure RU2245712C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9915625.9A GB9915625D0 (en) 1999-07-02 1999-07-02 Method
GB9915625.9 1999-07-02

Publications (2)

Publication Number Publication Date
RU2001134298A true RU2001134298A (en) 2003-08-27
RU2245712C2 RU2245712C2 (en) 2005-02-10

Family

ID=10856599

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2001134298/14A RU2245712C2 (en) 1999-07-02 2000-07-03 Method for applying cortisol antagonists at treating heart failure

Country Status (16)

Country Link
US (1) US6881739B1 (en)
EP (1) EP1196152A1 (en)
JP (1) JP4039482B2 (en)
KR (1) KR100623166B1 (en)
AU (1) AU780152B2 (en)
CA (1) CA2375751A1 (en)
CZ (1) CZ300888B6 (en)
GB (1) GB9915625D0 (en)
HU (1) HUP0202339A3 (en)
MX (1) MXPA01013465A (en)
NO (1) NO324395B1 (en)
NZ (1) NZ516239A (en)
PL (1) PL202859B1 (en)
RU (1) RU2245712C2 (en)
SK (1) SK285845B6 (en)
WO (1) WO2001001971A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642236B1 (en) * 1998-12-14 2003-11-04 Cortendo Ab Methods for prophylactic treatment of cardiovascular disease with inhibitor of cortisol synthesis
SE0001899D0 (en) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
GB0118300D0 (en) * 2001-07-26 2001-09-19 Cortendo Ab Formulations
RS44304A (en) 2001-11-22 2007-06-04 Biovitrum Ab., Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
DE50213170D1 (en) * 2002-09-04 2009-02-12 Fraunhofer Ges Forschung Use of a means for the treatment of cardiac hypertrophy
KR101387910B1 (en) * 2005-01-10 2014-04-25 콜텐도 인베스트 아베 Methods and compositions for treating diabetes, metabolic syndrome and other conditions
BRPI0719835A2 (en) 2006-10-02 2014-05-06 Cortendo Invest Ab KETOCONAZOLE ENANTIOMER IN HUMANS
WO2013103687A2 (en) * 2012-01-03 2013-07-11 Rhode Island Hospital Treatment of heart failure and sudden cardiac death

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US460314A (en) * 1891-09-29 George a
US4603141A (en) * 1984-11-30 1986-07-29 Giles Thomas D Oral clonidine treatment of congestive heart failure
US5175144A (en) * 1988-11-29 1992-12-29 The Johns Hopkins University Method of retarding the progression of chronic renal failure
GB9014221D0 (en) 1990-06-26 1990-08-15 Janssen Pharmaceutica Nv Method of treating alopecia
JP3918119B2 (en) 1993-01-21 2007-05-23 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Topical ketoconazole composition
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
US5756469A (en) * 1996-07-26 1998-05-26 Beale; Paxton K. Composition of pyruvate and anti-cortisol compounds and method for increasing protein concentration in a mammal
KR100840957B1 (en) * 1997-10-06 2008-06-24 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 Methods for Treating Psychosis Associated with Glucocorticoid Related Dysfunction
SE9803272D0 (en) 1998-09-25 1998-09-25 Kerstin Uvnaes Moberg A drug for cell regeneration
AU1036999A (en) * 1998-10-27 2000-05-15 Roumen Antonov Use of antifungal agents for treating scleroses

Similar Documents

Publication Publication Date Title
CN105520924B (en) The combination medicine of 3- (3- dimethylamino -1- Ethyl-2-Methyl-propyl)-phenol and antiepileptic
EP2338516A3 (en) Multiple-variable dose regimen for treating TNF-alpha-related disorders
RU2000106597A (en) NEW APPLICATION OF BUDESONIDE AND FORMOTHEROL
RU2008116931A (en) APPLICATION OF N-DESMETHYLCLOSAPINE FOR TREATMENT OF NEUROPSYCHIATRIC DISEASES IN PEOPLE
EA200800881A1 (en) DOSAGE FORM OF PYRFENIDONE IN THE FORM OF CAPSULES WITH PHARMACEUTICALLY ACCEPTABLE EXCIPIENTS
EA200400881A1 (en) AZAARILPIPERAZINS
RU2009138446A (en) GALENE COMPOSITIONS OF ORGANIC COMPOUNDS
JP2008531714A (en) Pharmaceutical composition for the treatment and / or prevention of anxiety disorders
CA2426625A1 (en) Combination of fenofibrate and coenzyme q10 for the treatment of endothelial dysfunction
RU2002126615A (en) PRESCRIPTION RANOLASIN PROLONGED ACTION
JP2012529486A5 (en)
MX2007009187A (en) The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome.
RU2001134298A (en) The use of cortisol antagonists in the treatment of heart failure
ES2315640T3 (en) METHOD TO TREAT SERIOUS CARDIAC INSUFFICIENCY AND MEDICATION FOR THE SAME.
RU2004135563A (en) MEDICINE FOR TREATING AN INCREASED ACTIVITY OF THE BLADDER
JP2004537500A5 (en)
RU2002121546A (en) SUBSTANCES FOR THE TREATMENT OF PSORIASIS
RU2007101695A (en) MEDICINAL PRODUCT FOR TREATMENT OF DIABETES MELLITUS BASED ON EXENATIDE AND DALARGIN, APPLICATION AND METHOD OF TREATMENT
RU2007132971A (en) METHODS AND MATERIALS WITH TRANS-CLOMIPHENES FOR TREATMENT OF MEN'S INFERTILITY
RU2002129355A (en) APPLICATION OF FULVESTRANTS IN TREATMENT OF RESISTANT BREAST CANCER
RU2003130641A (en) KAPPA-OPIATE AGONISTS FOR TREATMENT OF DISEASES OF THE BLADDER
RU2002124141A (en) APPLICATION OF MIRTAZAPINE FOR TREATMENT OF SLEEP DISORDERS
RU2005131943A (en) MEDICINAL AND / OR PREVENTIVE MEANS FOR CHRONIC SKIN DISEASES
RU2005132163A (en) 2- (BUTYL-1-SULFONILAMINO) -N- [1 (R) - (6-METHOXYpyridin-3-IL) -PROPYL] BENZAMIDE, ITS APPLICATION AS A MEDICINAL PRODUCT, AND ALSO CONTAINING HIS PHARES
RU2004121780A (en) METHOD OF TREATMENT